

SYSTEMATIC REVIEW PROTOCOL

Title: “Safety and efficacy of pharmacotherapy used for the management of COVID 19: A systematic review and meta-analysis of randomized control trials”

Running Title: “Safety and efficacy of pharmacotherapy used for the management of COVID 19: A systematic review and meta-analysis of randomized control trials”

Authors details,

1. Dr. Sujit Kumar Sah^{Pharm D}

Research Scholar
Department of Pharmacy Practice
JSS College of pharmacy
JSS Academy of Higher Education and Research
SS Nagar, Mysuru-570015
Karnataka, India
sujitsah1913@gmail.com
ORCID: 0000-0002-6003-4910

2. Dr. Krishna Undela^{M. Pharm, PhD}

Associate Professor
Department of Pharmacy Practice
National Institute of Pharmaceutical Education and Research
Guwahati, Assam, India
krishnaundela@gmail.com
ORCID: 0000-0002-7480-8761

3. Dr. Sharad Chand^{Pharm D}

Research Scholar and Assistant Professor
Department of Pharmacy Practice
NGSM Institute of Pharmaceutical Sciences
Nitte (Deemed to be University)
Paneer, Deralakatte, Mangaluru-575018
Karnataka, India
sureechand193@gmail.com
ORCID: 0000-0002-5777-0589

4. Dr. Madhan Ramesh*^{M. Pharm, PhD}

Professor & Head
Department of Pharmacy Practice
JSS College of pharmacy
JSS Academy of Higher Education and Research
SS Nagar, Mysuru-570015
mramesh@jssuni.edu.in
ORCID:[0000-0002-4272-0204](https://orcid.org/0000-0002-4272-0204)

5. Dr. Subramanian R_{MD, PhD, PDF}

Associate Professor and Head
Department of Rheumatology & Immunology
JSS Medical College & Hospital
JSS Academy of Higher Education and Research
SS Nagar, Mysuru-570015
Karnataka, India
subsano5@gmail.com
ORCID: 0000-0002-7192-7271

6. Dr. Oliver Joel Gona_{Pharm D}

Research Scholar
Department of Pharmacy Practice
JSS College of pharmacy
JSS Academy of Higher Education and Research
SS Nagar, Mysuru-570015
Karnataka, India
gonaoj@gmail.com
ORCID: 0000-0001-9240-9951

7. Dr. Sophia M. George, _{Pharm-D}

Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences,
NitteDeralakatte, Mangaluru-575018
Karnataka, India
sophiamgeorge.108@gmail.com
ORCID: 0000-0001-8692-1895

8. Nandakumar UP, _{M pharm}

Department of Pharmacy Practice
NGSM Institute of Pharmaceutical Sciences, Nitte
Deralakatte, Mangaluru-575018
Karnataka, India
ORCID: 0000-0001-5619-4930

9. Santosh Aryal_{MPH}

Direct Coordinator
The Leprosy Mission Nepal
Sunsari and Morang
Nepal
ORCID: 0000-0001-7999-9491

10. Niharika P _{Pharm D Intern}

Department of Pharmacy Practice TVM College of Pharmacy
Ballari-583101
Karnataka, India

niharikasha04@gmail.com

11. Dr. C.S. Shastry M. Pharm, PhD
Department of Pharmacy Practice
NGSM Institute of Pharmaceutical Sciences
Nitte (Deemed to be University)
Paneer, Deralakatte, Mangaluru-575018
Karnataka, India
drcshastry@gmail.com

Corresponding Author,

Dr. Madhan Ramesh* M. Pharm, PhD
Professor & Head
Department of Pharmacy Practice
JSS College of Pharmacy
JSS Academy of Higher Education and Research
SS Nagar, Mysuru- 570 015
Karnataka, India.
+91-9901218640
E-mail: mramesh@jssuni.edu.in

Abstract

Background:

COVID-19 is a novel coronavirus, which is highly contagious and a threat to human health, spreading across nearly 235 countries, affecting 33.8 million and causing 1.01 million fatalities as of 22 September 2020. Researchers have invested tremendous efforts to develop vaccines or effective drug therapy but have not yet been fruitful. Hence, we planned to conduct this systematic review and meta-analysis to supplement the readers with comprehensive data and credible information on the safety and efficacy of essential pharmacotherapy during the pharmacological management of COVID-19.

Methods: The protocol will be designed based on the updated PRISMA-P 2015 guidelines. An elaborate search of electronic databases such as PubMed/Medline, Web of Science,

Scopus, The Cochrane Library, ClinicalTrials.gov, Google Scholar, Medrxiv and other potential databases for articles published during January 2020 to 10 October 2020 is planned to be conducted. Following this, randomized control trials published in English language that assess the safety and efficacy of pharmacotherapy versus placebo or standard of care or usual care will be evaluated for inclusion. The primary outcomes will include time to clinical recovery and the probability for the negative conversion of COVID-19. Secondary outcomes will quantify the proportion of patients relieved of symptoms, the all-cause mortality, morbidity, detection of viral RNA, time needed to achieve a negative viral load, ordinal scale changes, ventilator and oxygen requirements, length of hospital stay and the incidence of adverse and serious adverse events. RevMan V.5.3 computer software packages will be utilised to conduct an accurate statistical analysis of the study. The binary random-effects model will be used at a 95 % confidence interval to estimate the weighted effect size of dichotomous data and continuous data studies. The results of statistical analysis will be considered statistically significant when a p-value <0.05 is attained.

Results: Selected studies will be used to evaluate the safety and efficacy of pharmacotherapy used during the management of the novel COVID-19.

Conclusion: This study will be a qualitative and quantitative pool of comprehensive evidence regarding the safety and efficacy of pharmacotherapy on COVID-19.

PROSPERO registration: CRD42020205433

Safety and efficacy of pharmacotherapy used for the management of COVID 19: A systematic review and meta-analysis of randomized control trials

Introduction

On 11 March 2020, WHO coronavirus 2019 was declared as a global pandemic and it began to gain worldwide attention. The worsening circumstances required all the domains of health care to proactively engage in the development of immediate and effective strategies to tackle the further spread of the coronavirus. The increase in attention given to the virus was due to its high contagious potential accompanied by its enormous threat to human health and the global economy.(1) In December 2019, a new human coronavirus in the Hubei province of Wuhan, China, capable of causing human respiratory disease, severe pneumonia and death was first recorded. Soon, COVID-19 spread very rapidly beyond Wuhan to most of the nations resulting in complete locked down to avoid remission of the virus.(2,3) In February 2020, WHO and the International Committee on Virus Taxonomy named the causative agent as 'Coronavirus 2019' and 'Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)' respectively.(4,5) Until the 02nd of October 2020, COVID-19 has spread to about 235 countries, affecting nearly 33.8 million people and is responsible for a worldwide mortality of 1.01 million.(6)

SARS-CoV-2 is the largest single-stranded, strongly diversified, enveloped, positive-sense RNA virus that is typically found in bats and birds. Transmission to humans occur from these sources often causing acute respiratory distress syndrome (ARDS), which can lead to fatalities.(7,8) The projected mortality rate is an approximate ~3.8%, which is lower than MERS-CoV (37.1%) or SARS-CoV (10%), but more than ten times the rate of other infections.(9,10) The most frequently observed clinical symptoms in COVID-19 patients are fever, dry cough, dyspnoea, body pain and headache while sore throat, chest pain, diarrhoea, nausea, vomiting, haemoptysis, and conjunctival congestion are less commonly observed.

Majority of the confirmed COVID-19 patients are asymptomatic but the potential to transmit the virus continues to be high.(11,12)

RT-PCR and rapid antigen tests by collecting saliva swab tests (91% sensitivity) and nasopharyngeal swab test (98% sensitivity) were done to detect the presence of the COVID-19 infection.(13)

To provide adequate evidence of the safety and effectiveness of pharmacotherapy, a vast number of clinical trials were quickly registered on ClinicalTrials.gov. Until 2nd October 2020, approximately 3,494 studies related to COVID-19 and 1,976 interventional (clinical trials) studies have been registered in ClinicalTrials.gov. Out of 1,976 interventional trials, 134 had been completed, 74 were terminated, suspended or withdrawn and 21 are in the early phase I trial. 113 studies are currently in the phase I of trials, 270 are in phase II, 163 in phase III and 33 are presently in phase IV.(14) COVID-19 is particularly challenging due to the lack of well-established evidence concerning the safety and effectiveness of therapies and treatment protocols for COVID-19. A large number of potential drug candidates for the treatment of COVID-19 such as antiretrovirals: remdesivir, lopinavir/ritonavir, antimalarial: hydroxychloroquine, chloroquine, immunosuppressive agents, angiotensin-converting enzyme 2 (ACE2) inhibitors, non-steroidal anti-inflammatory agents (NSAIDs) and conventional plasma therapy have emerged for use as adjuvants. However, unfortunately, these drug candidates are becoming controversial over time due to various safety and efficacy concerns.(15,16) This may be due to the current lack of a large sample size and the short duration over which studies were conducted. Therefore, we aimed to conduct this systematic review and meta-analysis and expect it to be a credible source of comprehensive information on the safety and efficacy of pharmacotherapy during the management of COVID-19.

Methods

Protocol registration

Protocol for this study was designed based on the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statements (17) and has been registered at PROSPERO (CRD42020205433).

Data sources

We will conduct a comprehensive search of electronic databases such as PubMed/Medline (<https://www.ncbi.nlm.nih.gov/pubmed/>), Web of Science (<https://clarivate.com/web-of-science-core-collection/>), Scopus (<https://www.scopus.com/>), The Cochrane Library (<http://www.cochranelibrary.com/>), ClinicalTrials.gov (<https://www.clinicaltrials.gov/>), Google Scholar (<https://scholar.google.com/>), Medrxiv (<https://www.medrxiv.org/>) and other potential databases. Articles published during January 2020 to 10 October 2020 will be included for analysis. The study is planned to be completed by 30th October, 2020. The references of key articles will be identified through hand searches. The human studies (randomized control trials) published in English language that evaluated the safety and efficacy of pharmacotherapy versus placebo or standard of care or usual care will be considered for review as well.

Search strategies

Key words or relevant texts that will be used to conduct a rigorous comprehensive literature search are pharmacotherapy, COVID-19 and study designs including drug therapy, antiviral agents, remdesivir, GS-573, lopinavir-ritonavir drug combination, oseltamivir, dolutegravir, indinavir, arbidol, antimalarials, hydroxychloroquine and chloroquine were reviewed for analysis. Immunosuppressive agents, glucocorticoids, dexamethasone, antirheumatic agents, tocilizumab, sarilumab, biological products, antibodies, monoclonal, anti-bacterial agents,

In order to conduct the search within other scientific databases, this search strategy will be adopted and the relevant key terms will be amended as necessary.

Eligibility Criteria:

Eligibility for this study will be evaluated based on the PICOS (populations, interventions, comparison, outcomes, and study designs) format.

Study population

- Patients who have a positive COVID-19 diagnostic report using the RT-PCR or serological methods
- Patients of any age, gender and race
- Subjects at any clinical stage of illness (mild to serious conditions) are eligible for inclusion
- Patients with or without other comorbidities

Intervention

- Drug therapy or vaccines of any dose and combinations

Comparison

- Placebo or standard care or usual care

Outcome measures

Both primary and secondary outcomes will be given importance. The primary outcomes will include the time to clinical recovery and the probability of a negative conversion of COVID-19. The secondary outcomes include a computation of the proportion of patients who experienced symptomatic relief, a measurement of all-cause mortality, morbidity, detection of viral RNA, time taken to achieve negative viral load, frequency of progression to respiratory illness, quantified body temperatures and time taken to recover from cough.

Additionally, impact on laboratory and radiological parameters, ordinal scale changes, ventilation and oxygen requirements, ICU admission rate, duration of hospitalization, time for discharge, rate of development of severe infections or complications, incidence of adverse outcomes (common and rare) and serious adverse events were also among the other listed secondary outcomes that would be measured by the study. The results of these consequences will be statistically described as mean, median, percentile and number of days (such as on the 7th, 14th and 28th day).

Study Designs

- Randomized control trials

Exclusion criteria

- Wrongly diagnosed or an unconfirmed diagnosis of COVID-19
- Patients using ayurvedic and homeopathic agents or any other form of conventional treatment
- Literatures such as non-randomized control trials, observational studies, retrospective studies, commentaries, notes and abstracts will be excluded.
- Paper reports with a total sample size of less than 10 recruits.
- Records with missing information or those that were unable to gather information

Study selection

The records will be retrieved from the above mentioned databases by using the above described search strategies. The extracted data will be transferred to Mendeley for the removal of duplicates. After the elimination of duplicates, titles and abstracts will be screened and reviewed independently by three authors to check for the satisfaction of the outlined eligibility criteria. Each review author will be blinded towards any information about journals and authors of the paper. Any disagreement during the selection process while checking for the eligibility of studies will be resolved through discussion with a fourth author.

Data extraction

Three reviewers will independently extract qualitative data from the selected studies that have mentioned the first author of the study, publication year, country, study setting, study design with the blinding status specified, patient's demographics details (age and gender), total sample size, sample in intervention and control group, loss of follow-ups, details on interventions (such as drug name, dose, duration of therapy), comparators (placebo or standard care or usual care), duration of follow-ups, outcomes measured (both primary and secondary) and risk of bias. In order to summarize the findings, changes that have occurred from baseline till the end of follow-up, the difference in changes within groups and between groups, significance level at 95% confidence interval and the status of findings that were favourable for the intervention group will be quantified and mentioned. The data will be extracted into Microsoft Excel and transferred into suitably designed data collection forms in Microsoft Word. Following which, the results will be tabulated as tables and expressed as figures. After data extraction by independent review authors is completed, it will further be exchanged for critical analysis of the relevant information so that blinding will be eliminated. Any disagreements during the extraction of data will be resolved through constructive dialogue and discussions with the fourth author.

Assessments of reporting risk of bias

Three review authors will assess the risk of bias independently using the Cochrane Risk of Bias (RoB). The risk of bias will be categorised as 'low', 'unclear' and 'high' based on essential domains including randomization sequence generation, concealment of allocation, blinding of participants and personnel, blinding of outcomes assessment, incomplete outcome data, selective reporting, and other bias. The decision on the risk of bias will be transferred to computer-based RevMan V.5.3. in order to generate an image of risk of bias graph and risk of

bias summary. Any conflicts on judgment will be resolved through conversations among the authors of the review.

Statistical analysis

In this review, the scope for meta-analysis is limited due to the wide range of outcomes that are evaluated. However, if at least two studies indicate homogeneity with similar interventions and outcomes, a meta-analysis will be performed. RevMan V.5.3 computer software packages will be used to perform all statistical analysis. The dichotomous data obtained will be used to quantify the occurring events while mean with standard deviations will be provided to represent continuous data. The binary random-effects model will be used at a 95 % confidence interval to estimate the weighted effect size of studies which will be summarised using risk ratios. Both the Chi-squared test and I^2 testing will be done to estimate the heterogeneity between studies. An I^2 value >50% will be described as the presence of moderate to high heterogeneity. All statistical results will be considered statistically significant when the p-value is measured to be less than 0.05.

Sub-group analysis

A subgroup analysis will be carried out in the presence of relevant data. The analysis carried out might include subgroups of studies conducted country-wise, subject characteristics and the overall adverse effects of drugs.

Sensitivity analysis

After a subgroup analysis is performed, if a substantial heterogeneity is noticed in the included trials then additional tests will be carried out to further investigate the source of heterogeneity for this systematic review. If more than ten studies will be available then a funnel plot will be drawn to analyse for the risk of reporting bias.

Addressal of missing data

If any relevant data is missing or incomplete, review authors will engage themselves to actively search for the original sources or contact authors through mail to obtain any missing information. If it is not possible for missing data to be retrieved, then the study will be excluded from the analysis.

Ethics and dissemination

In this review, previously published data will be used for the synthesis of data . Therefore, provision for ethical approval and informed consent will not be required. This study is scheduled to be written and will be published or presented in peer review journals and conferences.

Disclosures of funding

This study was not funded or supported by any organization or industry which may have influenced this study at any stage of review.

Discussion

Most of the potential drug therapies rapidly went under trial because of the observed beneficial effects during the occurrence of previous epidemics such as MERS- CoV and SARS-CoV. Some drugs have shown beneficial effects during in-vitro preclinical trails.(18) However, safety and efficacy issues such adverse effects, a nil reduction of viral load, drug-drug interactions for majority of the drugs remain a cause of controversy and they are highly likely to be ineffective. Hence, it is required to pay more attention to these facets in order to establish the safety and efficacy of pharmacotherapy used for the treatment of COVID-19.

The main objective of this study is to provide comprehensive and accurate evidence on the security and therapeutic efficacy of available pharmacological measures. The authors of this review firmly believe that the most promising therapeutic strategies to control and cure COVID-19 can be concluded from the findings of this review. This will enable us to offer guidance for the future clinical management of the confirmed COVID-19 cases.

References

1. Sunil Nepal, Sudip Nepal, C.S. Shastry et al. Impact of COVID-19 on Mental Dimension of Health: A Sensitive Issue to be Addressed at the Earliest. *Current Psychiatry Research and Reviews*. 2020;16:1. <https://doi.org/10.2174/2666082216999200918162639>
2. Singhal T. Review on COVID19 disease so far. *Indian J Pediatr*. 2020;87(4):281–6.
3. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. *Lancet*. 2020;395(10223):470–3.
4. Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus pandemic in


- history. *Biomed J.* 2020;xxx(xxxx):1–6.
5. Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): An update. *Cureus.* 2020;12(3):1–13.
 6. WHO Coronavirus Disease (COVID-19) Dashboard. Available from: <https://covid19.who.int/>
 7. Guo YR, Cao QD HY et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. *Mil Med Res.* 2020;7(11):1–10.
 8. Mohan K, Mohapatra S, Sharma P, Sharma S. Study and overview of the novel coronavirus disease (COVID-19). *Sensors Int [Internet].* 2020;1(100037):1–14. doi.org/10.1016/j.sintl.2020.100037
 9. Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). *J Microbiol Biotechnol.* 2020;30(3):313–24.
 10. Kaushik S, Kaushik S, Sharma Y, Kumar R, Yadav JP. The Indian perspective of COVID-19 outbreak. *VirusDisease.* 2020;31(2):146–53. doi.org/10.1007/s13337-020-00587-x
 11. Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; A narrative review for emergency providers. *Am J Emerg Med.* 2020;38:1488–93. doi.org/10.1101/2020.08.19.20177980
 12. Adhikari SP, Meng S, Wu Y, Mao Y, Ye R, Wang Q, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control coronavirus disease (COVID-19) during the early outbreak period: a scoping review. *Dis Poverty.* 2020;9(29):1–12. doi: 10.21203/rs.2.24474/v1
 13. Czumbel LM, Kiss S, Farkas N, Mandel I, Hegyi A, Nagy Á, et al. Saliva as a

candidate for COVID-19 diagnostic testing: A meta-analysis. *Front Med.* 2020;7:1–36.

doi: 10.3389/fmed.2020.00465

14. <https://clinicaltrials.gov/ct2/results?cond=COVID-19>.
15. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19). *JAMA - J Am Med Assoc.* 2020;323(18):1824–36.
16. Wu R, Wang L, Kuo HCD, Shannar A, Peter R, Chou PJ, et al. An update on current therapeutic drugs treating COVID-19. *Curr Pharmacol Reports.* 2020;6(3):56–70.
17. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015;4(1):1–9.
18. Jomah S, Asdaq SMB, Al-Yamani MJ. Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. *J Infect Public Health.* 2020;13(9):1187–95. doi.org/10.1016/j.jiph.2020.07.013

PRISMA 2009 Flow Diagram






Figure 1: Flowchart of Study Selection Process (PRISMA)